IP Library Granted Patent US 8,791,242
Granted Patent B2
US 8,791,242 · App. 13/294,680 · Granted Jul 29, 2014

Canine thymic stromal lymphopoietin protein and uses thereof to treat allergic symptoms

Inventors: Jeanine D. Mattson (Palo Alto, CA); Daniel M. Gorman (Palo Alto, CA); Rene de Waal Malefyt (Palo Alto, CA); Mohamad A. Morsey (Elkhorn, NE)
Assignee: Intervet Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,791,242
App. No.
13/294,680
Granted
Jul 29, 2014
Kind
B2
Abstract

The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.

Claims (14)

1. An isolated anti-canine thymic stromal lymphopoietin protein (TSLP) antibody elicited in a mammal or in a mammalian hybridoma system with a composition comprising a TSLP or an antigenic fragment thereof, wherein said TSLP comprises an amino acid sequence that has 90% or greater identity to the amino acid sequence of SEQ ID NO: 2, excluding the 28 amino acid residue signal sequence.

2. The anti-canine TSLP antibody of claim 1 , wherein the antibody is a monoclonal antibody.

3. The anti-canine TSLP antibody of claim 2 wherein the monoclonal antibody is caninized.

4. An isolated anti-canine thymic stromal lymphopoietin protein (TSLP) antibody elicited in a mammal or in a mammalian hybridoma system, obtained with a composition comprising a fusion protein;

wherein said fusion protein comprises a thymic stromal lymphopoietin protein (TSLP) or an antigenic fragment thereof; and

wherein said TSLP comprises an amino acid sequence that has 90% or greater identity to the amino acid sequence of SEQ ID NO: 2, excluding the 28 amino acid residue signal sequence.

5. The anti-canine TSLP antibody of claim 4 , wherein the antibody is a monoclonal antibody.

6. The anti-canine TSLP antibody of claim 5 wherein the monoclonal antibody is caninized.

7. A method of treating allergic symptoms in an atopic canine comprising administering an effective amount of the anti-canine TSLP antibody of claim 1 .

8. A method of treating allergic symptoms in an atopic canine comprising administering an effective amount of the anti-canine TSLP antibody of claim 2 .

9. A method of treating allergic symptoms in an atopic canine comprising administering an effective amount of the anti-canine TSLP antibody of claim 3 .

10. A method of treating allergic symptoms in an atopic canine comprising administering an effective amount of the anti-canine TSLP antibody of claim 4 .

11. A method of treating allergic symptoms in an atopic canine comprising administering an effective amount of the anti-canine TSLP antibody of claim 5 .

12. A method of treating allergic symptoms in an atopic canine comprising administering an effective amount of the anti-canine TSLP antibody of claim 6 .

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
CHANGE OF NAME Recorded Jun 9, 2014
From: SCHERING-PLOUGH ANIMAL HEALTH CORPORATION
To: INTERVET INC.
Reel/Frame 033105/0272 →
Continuity (4)
Division 12721002 · Mar 10, 2010
Division 11954143 · Dec 11, 2007
Provisional Application 60875135 · Dec 14, 2006
Related Publication 20130183291A1 · Jul 18, 2013